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Biogenesis of Pro-senescent 
Microparticles by Endothelial 
Colony Forming Cells from 
Premature Neonates is driven 
by SIRT1-Dependent Epigenetic 
Regulation of MKK6
Stéphanie Simoncini1, Anne-Line Chateau1,6, Stéphane Robert1, Dilyana Todorova1, Catherine 
Yzydorzick2, Romaric Lacroix1, Isabelle Ligi3, Laurence Louis4, Richard Bachelier1, Umberto 
Simeoni2, Frédérique Magdinier4, Françoise Dignat-George1,5 & Florence Sabatier1,6
Senescent cells may exert detrimental effect on microenvironment through the secretion of soluble 
factors and the release of extracellular vesicles, such as microparticles, key actors in ageing and 
cardiovascular diseases. We previously reported that sirtuin-1 (SIRT1) deficiency drives accelerated 
senescence and dysfunction of endothelial colony-forming cells (ECFC) in PT neonates. Because preterm 
birth (PT) increases the risk for cardiovascular diseases during neonatal period as well as at adulthood, 
we hypothesized that SIRT1 deficiency could control the biogenesis of microparticles as part of a 
senescence–associated secretory phenotype (SASP) of PT-ECFC and investigated the related molecular 
mechanisms. Compared to control ECFC, PT-ECFC displayed a SASP associated with increased release 
of endothelial microparticles (EMP), mediating a paracrine induction of senescence in naïve endothelial 
cells. SIRT1 level inversely correlated with EMP release and drives PT-ECFC vesiculation. Global 
transcriptomic analysis revealed changes in stress response pathways, specifically the MAPK pathway. 
We delineate a new epigenetic mechanism by which SIRT1 deficiency regulates MKK6/p38MAPK/Hsp27 
pathway to promote EMP biogenesis in senescent ECFC. These findings deepen our understanding of 
the role of ECFC senescence in the disruption of endothelial homeostasis and provide potential new 
targets towards the control of cardiovascular risk in individuals born preterm.
Preterm (PT) birth is associated with an increased risk of vascular-related diseases during the neonatal period, 
such as bronchopulmonary dysplasia and retinopathy, as well as early in adulthood, including hypertension and 
emphysema1–4. Adverse early programming may explain such association and influence cardiovascular risk over 
the life course by acting on the vascular bed. Vascular alterations are major determinants and include an increase 
in arterial stiffness, a reduction in microvascular density because of incomplete vasculogenesis, and an impair-
ment of endothelial function5, 6.
Endothelial Colony Forming Cells (ECFC) are a relevant subset of endothelial progenitor cells that mainly reside 
in vessel wall, circulate at low frequency in the blood, and support vascular repair and de novo vessel formation7–9. 
A growing body of evidence supports their role as potential biomarkers and therapeutic targets in PT birth5, 10, 11. 
Among the factors that can alter cord blood ECFC functions in premature neonates, we recently demonstrated the 
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involvement of accelerated senescence driven by sirtuin-1 (SIRT1) deficiency, which determines their vasculogenic 
defects12. Senescence of ECFC, limiting the ability for vascular healing, has emerged as an important contributor to 
the disruption of endothelial integrity developing under cardiovascular risk factors8, 13, 14.
In addition to the loss of specialized functions of the cells themselves, the detrimental effect of cells display-
ing stress-induced premature senescence (SIPS) might be due to an altered secretory phenotype referred to as 
senescence-associated secretory phenotype (SASP). According to the cell type and senescence context text15, 
SASP components such as cytokines, proteases, and extracellular vesicles (EV)16, 17 modulate the behavior of 
neighboring cells in a paracrine and/or autocrine manner, alter the cellular microenvironment, and can contrib-
ute to the functional decline of tissues and the progression of aging-related diseases18–20. This concept is mainly 
based on in vitro studies of fibroblasts undergoing excessive replication, but to our knowledge no ex vivo studies 
have characterized endothelial SAPS in the context of SIPS associated to cardiovascular risk factors.
Moreover, among the SASP components, previous studies have mainly focused on secreted soluble factors. 
However, endothelial cells, like most cells, release different types of extracellular vesicles EV, including micropar-
ticles. Microparticles are small heterogeneous membranous structures (0.1–1 µm) released under normal or 
pathological conditions, which can mediate phenotypic modification and reprogramming of cell function, in 
their local environment or at remarkable distance from their site of origin21. Circulating endothelial microparti-
cles (EMP) are increased in conditions of vascular stress or dysfunction and have been demonstrated to behave 
not only as markers of endothelium damages22, but also as effectors in the control of vascular homeostasis23. EMP 
display variety of phenotypic and functional characteristics highly dependent on the functional state of the releas-
ing cells and the mechanisms underlying the vesiculation process.
Despite the clinical importance of EMP in ageing and cardiovascular diseases, little is known about the mech-
anisms linking SIPS and EMP biogenesis. Herein, using senescent ECFC isolated from cord blood of PT neonates, 
we aimed to investigate whether SIRT1 deficiency could activate signaling pathways inducing EMP formation. 
Our study evidenced that PT-ECFC acquire a specific SASP including EMP able to propagate endothelial senes-
cence. Moreover, we delineate a new epigenetic mechanism by which SIRT1 deficiency regulates MKK6/p38MAPK 
pathway to promote EMP biogenesis in senescent ECFC.
Results
PT-ECFC displayed a senescence-associated secretory phenotype. To determine whether 
PT-induced senescence of ECFC could induce a SASP, we first assessed the secretion profiles of ECFC from 
preterm neonates (PT-ECFC) and control ECFC (CT-ECFC) using cytokine antibody arrays (Figure S1A). After 
48 h of basal culture, higher levels of cytokines (notably IL6, IL8, GRO and RANTES, previously identified as 
SASP components24–26 were detected in the conditioned media from PT-ECFC compared CT-ECFC (Fig. 1A, 
Figure S1B,C). Using an ELISA, we confirmed the enhanced secretion of IL6, a highly conserved SASP com-
ponent shown previously elevated in endothelial cells at replicative senescence27, by PT-ECFC (Fig. 1B, upper 
panel). Strikingly, the IL6 level positively correlated with the percentage of senescent cells (Fig. 1B, lower panel) 
and inversely correlated with gestational age (Figure S2A).
We then used the qNano system to investigate whether this secretory profile was accompanied by a modula-
tion in EV release. The size distribution of the unfractionated EV ranged from approximately 50 to 1,000 nm in 
diameter, indicating the presence of a mixed population of exosomes (≤100 nm) and EMP (0.1 to 1 µm) (Fig. 1C). 
No significant change in exosomes concentration was observed (Fig. 1D, upper panel), while the media from 
PT-ECFC exhibited significantly higher concentrations of particles greater than 200 nm compared to that of CT- 
ECFC (approximately 2.5-fold increase; Fig. 1D, lower panel and 1C), indicating enhanced EMP production.
Consistently, flow cytometry analysis of the PT-conditioned media confirmed the higher levels of EMP, 
defined as Annexin V+events, with size ranging from 0.1 to 1 µm, compared to the CT group (Fig. 1E). EMP 
release positively correlated with the percentage of senescent cells (Fig. 1F) and inversely correlated with gesta-
tional age (Figure S2B). We also observed a significant correlation between EMP release and IL6 secretion, linking 
the cytokine secretory profile with EMP biogenesis in senescent PT-ECFC (Figure S2C). Altogether, these data 
indicate that in the context of SIPS, PT-ECFC display a SASP associated with increased EMP release.
EMP from PT-ECFC mediate a paracrine induction of senescence in endothelial cells. We per-
formed in vitro assays to investigate the senescence-induction capacity of the EMP part of the conditioned media 
from CT- or PT-ECFC. Early-passage HUVEC were used as target cells to exclude the confounding effects of rep-
licative senescence. HUVEC exposed to CT-media for 48 h grew normally, whereas those treated with PT-media 
displayed higher levels of positive staining for SA-β-galactosidase (Fig. 2A left panel; Figure S3A), associated with 
a significant reduction in BrdU incorporation (Fig. 2B left panel). Cell cycle distribution analysis revealed drastic 
cell cycle arrest at the G0/G1 phase for HUVEC exposed to PT-media (Fig. 2C). Interestingly, EMP depletion of 
the PT-media, as determined by the qNano system (Figure S4), significantly attenuated the deleterious effects of 
the total media on the senescent phenotype and mitotic potential of HUVEC. Thus, the paracrine pro-senescent 
effect of PT-conditioned media might involve, at least in part, the EMP fraction.
To sustain the role of EMP, HUVEC were also treated with an adjusted concentration of CT-EMP or PT-EMP 
purified from the conditioned media. Twenty-four hours after treatment, PT-EMP significantly increased the 
SA-β-galactosidase activity and senescence-associated morphological changes in HUVEC compared to treatment 
with CT-EMP or vehicle (Fig. 2A right panel, Figure S3B). In addition, HUVEC exposed to PT-EMP displayed 
a significant increase in the level of the senescence-associated p21 protein, whereas the p16 level was unchanged 
(Figure S3C). Consistent with the senescent phenotype, PT-EMP-treated cells also exhibited significantly reduced 
proliferation, with a marked increase in G0/G1 (Fig. 2B right panel and 2D).
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To test whether the EMP fraction from PT-ECFC could also contribute to the SASP pro-inflammatory poten-
tial, we evaluated if the pre-treatment of HUVEC with total or EMP-depleted conditioned media and puri-
fied EMP or the corresponding vehicle affected monocyte adhesion. A significant increase in the adhesion of 
calcein-AM-labeled monocytes was observed when HUVEC were co-incubated with PT-conditioned media, but 
not with CT-conditioned media (Fig. 2E). However, EMP depletion did not significantly prevent the pro-adhesive 
effect of PT-conditioned media. Consistently, monocyte adhesion to HUVEC was only slightly affected by puri-
fied PT-EMP compared to CT-EMP and the vehicle (Fig. 2F). Taken together, these data indicated that the EMP 
play a prominent paracrine role in senescence induction rather than in the pro-inflammatory response orches-
trated by the SASP of PT-ECFC.
SIRT1 level drives PT-ECFC vesiculation. Our previous study showed that SIRT1 defect drives acceler-
ated PT-ECFC senescence12. Thus, we asked whether SIRT1 might control PT-ECFC vesiculation. Consistently, 
we found a significant inverse correlation between EMP release and the SIRT1 protein level in ECFC (Fig. 3A). 
In addition, 48 h after transient transfection of PT-ECFC with a SIRT1-encoding vector, we observed as expected 
a significantly reduced SA-β-gal activity and senescence-associated morphological changes compared to cells 
transfected with an empty vector (Fig. 3B upper panel). Interestingly, SIRT1 overexpression was associated with 
a significant decrease in the level of released EMP (Fig. 3B lower panel). Moreover, the addition of nicotinamide 
(NAM), a well-established inhibitor of SIRT1 activity28, counteracted the effects of SIRT1 overexpression on EMP 
release and PT-ECFC senescence phenotype (Fig. 3B). Because we previously observed that resveratrol (RSV) 
reverses PT-ECFC senescence by inducing SIRT1 expression12, we tested whether RSV could also prevent EMP 
Figure 1. Prematurity modulates a subset of SASP. (A) Analysis of factors secreted by CT- and PT-ECFC 
using antibody arrays. CT-conditioned media signals were used as the baseline. The heat maps key represents 
log2-fold changes of PT-media from the baseline. Signals higher and lower than the baseline are highlighted 
in yellows and blue respectively. Factors that differed significantly between the CT- and PT-media are 
represented by an asterisk (*). (B) An ELISA assay confirmed that IL6 levels were significantly increased in 
conditioned media from PT vs. CT cells (upper panel, N = 9 vs. 5). Correlation between the secreted IL6 
levels and the senescence percentage of ECFC (lower panel). (C) The qNano profiles of the concentrations 
of unfractionated raw vesicles for CT and PT-media using NP150 and NP400 nanopores (N = 5 vs. 6). (D) 
Size distribution of endothelial vesicles from CT- and PT-media, as estimated by qNano. The figure depicts 
the diameter of the vesicles (in nm) versus the normalized concentration of vesicles (in particles/ml). 60-nm 
bin size. (E) Comparison of levels of Annexin-V+ EMP of CT- and PT-media (N = 11 vs. 16). Representative 
plots and quantification of EMP measurements by flow cytometry (size of 0.1–1 µm that stained positively 
for Annexin-V). (F) Correlation between Annexin-V+ EMP levels and the senescence percentage of ECFC 
(N = 20). The data for all the bar graphs are presented as the means ± SEM. (Statistical analyses: Mann Whitney, 
Unpaired t-test; *p < 0.05, **p < 0.01, ***p < 0.001).
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release in addition to senescence onset. As expected, 48 h of treatment with 1 μM RSV reduced the percentage 
of senescent PT-ECFC (Fig. 3C upper panel). In addition, RSV treatment significantly reduced EMP release by 
PT-ECFC to a level close to that of CT-ECFC, and this effect was abrogated by NAM (Fig. 3C lower panel), sug-
gesting that RSV inhibits senescence-associated EMP release by PT-ECFC in a SIRT1-dependent manner.
To further uncover the causal relationship between SIRT1 downregulation and enhanced endothelial vesic-
ulation, we analyzed the consequences of siRNA-mediated SIRT1 knockdown at both the mRNA and protein 
levels in CT-ECFC (Figure S5A,B). A significant increase in SA-β-gal activity was observed (Fig. 3D upper 
panel), whereas no apoptotic signal was detected using Annexin-V/7-AAD staining (Figure S5C). Growth arrest 
of senescent CT-ECFC, attested by a marked increase in p16Ink4 expression, in the absence of modulation of 
the p53/p21WAF pathways suggested that SIRT1 knockdown in CT-ECFC mimics the previously described12 
PT-ECFC senescence phenotype (Figure S5A-B). Decreased SIRT1 expression in CT-ECFC was accompanied 
by the significant upregulation of EMP release (Fig. 3D lower panel). Altogether, these data indicate that reduced 
SIRT1 level drives the senescence-associated release of EMP by PT-ECFC.
Microarray Analysis reveals an upregulation of the MKK6-p38MAPK pathways in PT-ECFC. To 
explore the molecular mechanisms underlying the SIRT1-dependent EMP production, we performed global 
gene expression profiling. As shown in Fig. 4A, after array normalization, the gene expression profiles of CT- 
and PT-ECFC were reduced to 2 principal components, demonstrating that these cells had distinct profiles. 
Subsequently, 41,087 probes that passed our quality control threshold were assessed for differential expression. 
Overall, hierarchical clustering identified 973 probes that were differentially regulated between CT and PT-ECFC. 
Figure 2. EMP components of the PT-SASP are key mediators of paracrine senescence. (A) Quantification of 
positive senescence-associated (SA) β-galactosidase staining in HUVEC exposed for 48 h to conditioned media 
(CM) ± depleted in EMP (left) or vehicle (SN), CT-EMP or PT-EMP (right). (HUVEC, N = 4; N = 6 CT vs. 7 
PT). (B) Proliferation was assessed in a BrdU incorporation assay. The impact of CM ± depleted in EMP (left). 
Impact of purified EMP (right). (HUVEC, N = 4; N = 6 CT vs. 7–9 PT). (C,D) Cell cycle distribution by flow 
cytometry. DNA content in each cell cycle phase in HUVEC was analyzed by flow cytometry after propidium 
iodide staining. Representative histograms (upper panel) are from HUVEC treated with CM ± depleted in EMP 
(C) or purified EMP from CT- and PT-ECFC (D). Graph (lower panel) represents a mean percentage of cells at 
different phases of the cell cycle determined by the DNA content ± SD for 4 independent HUVEC treated with 
6 CT vs 7–9 PT samples. *p < 0.05; **p < 0.01; ***p < 0.001 (E,F) THP1 monocytic cell line adhesion assay on 
HUVEC exposed overnight to (E) CM ± depleted in EMP or (F) vehicle (SN), CT-EMP or PT-EMP. Data are 
represented as means ± SEM for 4 independent HUVEC treated with 4 CT vs 7 PT independent samples. Each 
experiment was carried out in triplicate. *p < 0.05.
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Of these probes, 439 (253 genes) and 534 (476 genes) were up- and downregulated respectively, in PT-ECFC 
(≥1.5 fold-change, p ≤ 0.05; Fig. 4B, Tables S2–3).
To provide a cohesive view of the biological functions and pathways associated with the expression changes 
of the PT genes, we integrated multiple resources. DAVID was used to determine which biological process was 
over-represented. The upregulated genes had a strong association with stress response, negative regulation of 
proliferation and cell cycle, protein localization and exocytosis, whereas the categories enriched for the down-
regulated genes were associated with cell growth and preservation of cell integrity, such as cell development, 
proliferation and apoptotic regulation (Fig. 4C, Tables S4–5). In addition, we performed pathway analysis to 
predict the transcriptional networks using the Finding Significant Pathway tools in GeneSpring GX. This analy-
sis revealed multiple enriched pathways, including the mitogen-activated protein kinase (MAPK), Wnt, insulin 
and DNA damage signaling pathways (Table S6). Collectively, these analyses identified an enrichment of genes 
involved in the MAPK pathways (Fig. 4D), which were previously implicated in both stress response, senescence 
and cytoskeleton reorganization19, 29, 30.
SIRT1 deficiency leads to increased senescence and vesiculation through the p38MAPK pathway 
activation in PT-ECFC. We then focused on the p38MAPK pathways and first evidenced that in PT-ECFC, 
low SIRT1 expression was accompanied by a significant activation of the p38MAPK pathway, as evidenced by 
increased phosphorylation of p38MAPK, without alteration of the total p38MAPK level (Fig. 5A). We further inves-
tigated the downstream MAPKAPK2/Hsp27 signaling to p38MAPK, which was reported to play a key role in actin 
cytoskeleton remodeling and blebs formation31, 32. We observed significant increase in the phosphorylation of 
both downstream signaling molecules MAPKAPK2 and Hsp27 (Fig. 5B) in PT-ECFC compared to CT-ECFC. 
Interestingly, we previously reported the upregulation of another downstream target of the p38MAPK pathway, the 
cyclin-dependent kinase inhibitor p16, in senescent PT-ECFC12. Application of SB203580, a p38MAPK activity 
Figure 3. SIRT1 defect drives the senescence-associated EMP release induced by prematurity. (A) Correlation 
between Annexin-V+EMP release and SIRT1 protein levels. Every dot represents a single sample collected from 
term or PT neonates (N = 17). (B–D) Representative images and the quantification of ECFC positive for SA 
β-galactosidase activity (original magnification ×20, scale bar, 49 µm) and the quantification of EMP release by 
flow cytometry using Annexin-V staining. (B) The effect of SIRT1 overexpression on PT-ECFC (48 h, N = 14). 
PT-ECFC were transiently transfected with pCMV-sport6 vector (Empty) or the pCMV-Sport6-SIRT1vector 
(SIRT1), and treated or not with nicotinamide (NAM, 1 mM). (C) The effect of SIRT1 modulation by resveratrol 
(RSV) treatment on PT-ECFC (48 h, N = 18, CT = 9). PT-ECFC were treated with solvent alone (NT) or 1 µM 
of resveratrol (RSV, in the presence or absence of 1 mM of NAM (D) The effect of SIRT1 silencing on CT-ECFC 
(48 h, N = 11). CT-ECFC were transiently transfected with control siRNA (siCT) or SIRT1 siRNA (siSIRT1). 
The data for all of the bar graphs are presented as the means ± SEM. (Statistical analysis: One-way ANOVA, 
t-test; *p < 0.05, **p < 0.01, ***p < 0.001).
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inhibitor33, significantly blocked the activation of MAPKAPK2/Hsp27 arm of p38MAPK signaling and reduced 
EMP release from PT-ECFC (Fig. 5C and D right panel) compared to DMSO-treated PT-ECFC, these effects 
occurring concomitantly with the attenuation of the senescence phenotype (Fig. 5D left panel; Figure S6A). 
These data suggest that p38MAPK via Hsp27 phosphorylation mediates senescence-associated release of EMP by 
PT-ECFC.
To investigate the relationship between SIRT1 and p38MAPK/MAKAPK2/Hsp27 pathways activation in the 
EMP release, we first evaluated the effects of SIRT1 overexpression using transient expression experiments and 
drug treatments in PT-ECFC. As shown in Fig. 5E, SIRT1 transfection into PT-ECFC significantly repressed 
p38MAPK and Hsp27 activation compared with that of PT-ECFC transfected with an empty vector, while total 
p38MAPK remain unchanged. Moreover, the addition of NAM counteracted the beneficial effect of SIRT1 over-
expression on p38MAPK pathway activation (Fig. 5F). Time course addition of RSV to PT-ECFC progressively 
induced a SIRT1 level increase associated with a gradual decrease in P-p38MAPK and P-Hsp27 levels (Figure S7). 
Conversely, SIRT1 knockdown in CT-ECFC using SIRT1 siRNA transfection increased p38MAPK activation 
and the phosphorylation of its target proteins compared to the control siRNA (Fig. 5G). Interestingly, inhibi-
tion of p38MAPK activity and MAPKAPK2 as well as Hsp27 phosphorylation with SB203580 partially blocked 
EMP release, concomitant to senescence, induced by SIRT1 knockdown in CT-ECFC (Fig. 5H,I, FigureS 8). 
Altogether these data indicate that SIRT1 defect, via the p38MAPK/MAPKAPK2/Hsp27 pathway activation, con-
trols senescence-associated EMP release.
SIRT1 deficiency leads to the upregulation of the p38MAPK pathway by increasing MKK6 expres-
sion in PT-ECFC. Having demonstrated the relationship between SIRT1 and p38MAPK pathway activation in 
senescence-associated EMP release, we then examined the potential molecular intermediate. Phosphorylation 
of p38MAPK is a downstream consequence of the activation of MKK3/6, upstream kinases, by phosphoryla-
tion (P-MKK3/6). Interestingly, in the above array analysis, marked differences were observed in the MKK6 
(MAP2K6) expression level (Fig. 4D, Table S2). We therefore investigated whether SIRT1-dependent p38MAPK 
pathway activation may occur through the modulation of MKK6 expression. Consistent with transcriptional 
Figure 4. Prematurity induces a distinct transcriptome profile in ECFC. (A) Principal component analysis 
(PCA) plot of the gene expression profiles across 4 CT (blue) and 11 PT-ECFC (red). Each point represents a 
single ECFC sample, whereas the distance between points is indicative of the global gene expression similarity, 
such that similar array profiles are positioned closer together. (B) The hierarchical clustering for differentially 
expressed genes detected by whole-genome microarray analysis of the mRNA obtained from CT- and PT-
ECFC. Genes in red: increased expression; genes in green: decreased expression. (C) Fold enrichment over 
chance for the Gene Ontology (GO) biological process of the Up-with-PT (red) or Down-with-PT (green) gene 
lists using DAVID (fold change ≥ 2, p ≤ 0.001). (D) The MAPK pathway in PT-ECFC. Pathway analysis was 
performed using SEA GeneSpring resources; differentially expressed genes are shown (yellow boxes, p ≤ 0.05), 
with the induction ratio derived from the microarray data.
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Figure 5. SIRT1 protects against senescence and vesiculation through the downregulation of the p38MAPK 
pathway activation in ECFC. (A) The level of P-p38 and total p38 were examined through Western blot analyses 
in CT- and PT-ECFC (N = 11 vs 18). (B) Western blot analysis of p38MAPK activation in CT- and PT-ECFC 
was performed by the determination of phosphorylation of MAPKAPK2 and Hsp27 (N = 11–18 vs 13–28) 
(C) Western blot analysis was performed to determine the levels of P_MAPKAPK2 and P-Hsp27 in PT-ECFC 
treated with 2 µM of the p38MAPK activity inhibitor, SB203580 (SB). (D) The effect of SB203580 treatment on 
CT- and PT-ECFC (2 µM, 48 h, N = 6 vs. 14) on senescence and EMP release. Left panel: quantification of ECFs 
positive for SA β-galactosidase activity. Right panel: quantification of EMP release by flow cytometry using 
Annexin-V staining. (E) The impact of SIRT1 overexpression on p38MAPK pathway activation in PT-ECFC 
(relative expression to empty; N = 8–11). (F) The impact of NAM on p38MAPK pathway activation (relative 
expression to SIRT1-transfected cells; N = 8–11) in PT-ECFC overexpressing SIRT1. (G) The impact of SIRT1 
silencing on p38MAPK pathway activation in CT-ECFC (relative expression to scrambled; N = 6–13). (H,I) 
The effect of SB203580 treatment on SIRT1-knockdown CT-ECFC was assessed on downstream effectors of 
p38MAPK (H, N = 4–7), as well as the percentage of ECFC positive for SA β-galactosidase activity (I, Left panel, 
N = 8) and EMP release (I, Right panel). The data for all of the bar graphs are presented as the means ± SEM. 
(Statistical analysis: One-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001). All blots correspond to 
representative images of blot bands.
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profiling data, we first evidenced that in PT-ECFC, low SIRT1 expression and p38MAPK pathway activation was 
accompanied by MKK6 upregulation at the mRNA and protein levels (Fig. 6A,B), and SIRT1 expression had a 
strong negative correlation with the MKK6 levels (Fig. 6C). Interestingly, both P-MKK3/6 and MKK6 were upreg-
ulated in PT-ECFC compared to CT-ECFC, while there was a decrease in MKK3 expression among the group. 
(Fig. 6D). Consistently, SIRT1 knockdown in CT-ECFC directly enhanced the mRNA and protein levels of MKK6 
(Fig. 6E,H), whereas MKK3 level was not change (Fig. 6H). By contrast, as shown in Fig. 6F and I, SIRT1 trans-
fection into PT-ECFC was associated with significant decreases in the mRNA and protein levels of MKK6 as well 
as MKK3/6 phosphorylation (Fig. 6I). The addition of NAM counteracted the beneficial effect of SIRT1 overex-
pression on MKK6 expression (Fig. 6G,J) and MKK3/6 activation (Fig. 6J). Similarly, the incubation of PT-ECFC 
with RSV resulted in the downregulation of MKK6, both at the mRNA and protein levels, concomitant to phos-
phorylation, along with p38MAPK and its effector activation in a time-dependent manner (Figure S7), suggesting 
that SIRT1 defect-induced upregulation of MKK6 may occur prior to the upregulation of P-MKK3/6. Collectively, 
these results indicate that the activation of the MKK6/p38MAPK pathway is, in part, regulated by SIRT1 through 
SIRT1-dependent MKK6 transcriptional modulation and participates in senescence-associated EMP release.
SIRT1 represses MKK6 in an epigenetic manner. To determine whether SIRT1 directly regulates the 
MAP2K6 gene, we performed chromatin immunoprecipitation (ChIP) assays. We selected 12 specific primer 
pairs encompassing the 5′ untranslated region (5′UTR) of the MAP2K6 gene, including the transcription start 
site (TSS), the enhancer sites within the first intron and the peaks enriched in histones H3K27ac and H3K9ac 
in HUVEC, described in the UCSC database34 (Fig. 7A). Within this 16,547-bp region, we found significant 
Figure 6. SIRT1 defect increased pMKK3/6 by increasing MKK6 levels. The SIRT1 and MKK6 mRNA (A) 
and protein (B) expression levels in CT-and PT-ECFC were assessed via RT-qPCR and Western blot analysis, 
respectively. (A) The impact of PT on the mRNA level (relative expression to CT; N = 13 CT vs. 16 PT). (B) 
The impact of PT on the protein level (relative expression to actin; N = 18 CT vs. 26 PT, representative blot). 
(C) The correlation between MKK6 and SIRT1 protein expression levels. Every plot represents a single sample 
collected from a patient (N = 24). (D) Western blot analysis of MKK3/6 activation in CT- and PT-ECFC was 
performed by the determination of phosphor-MKK3/6, MKK3 and MKK6 (N = 118 vs 28). (E–J) The impact of 
SIRT1 modulation on the activation of MKK3/6. SIRT1 and MKK6 mRNA (E–G) and protein (H–J) expression 
levels, along with MKK3/6 phosphorylation, were assessed via RT-qPCR and Western blot analysis, respectively. 
(E,H) The impact of SIRT1 silencing on the mRNA and protein expression of CT-ECFC (relative expression 
to scrambled; N = 12). (F,I) The impact of SIRT1 overexpression on mRNA and protein expression in PT-
ECFC (relative expression to empty; N = 7 and 11, respectively). (G,J) The impact of NAM on mRNA (relative 
expression to empty, N = 8) and protein expression (relative expression to SIRT1-transfected cells; N = −6–9) in 
PT-ECFC overexpressing SIRT1. The data for all of the bar graphs are presented as the means ± SEM. (Statistical 
analysis: t-test; *p < 0.05, **p < 0.01, ***p < 0.001). All blots correspond to representative images of blot bands.
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Figure 7. SIRT1 negatively regulates MKK6 transcription through epigenetic chromatin modification. (A) 
Genome browser view showing the genomic region surrounding the transcriptional start site (TSS, arrow) 
of human MAP2K6 (MKK6). Encode tracks illustrate the presence of H3K27ac and H3K9ac marks of the 
ChIP-seq and the promoter and enhancer regions in HUVEC. The annealing positions of primers used for the 
ChIP experiments are indicated at the bottom of the figure (B) ChIP assays were performed with chromatin 
prepared from CT-ECFC. The chromatin was immunoprecipitated with the antibody against SIRT1, and 
the precipitated genomic DNA was analyzed via RT-PCR using primers for different areas of the MAP2K6 
promoter and enhancer region. The actin promoter served as a negative control. (C and F) ChIP assays were 
performed with chromatin prepared from CT- or PT-ECFC (N = 9 vs. 6). Chromatin was immunoprecipitated 
with the antibodies against SIRT1 (C), H3 and H3K9Ac (F). (D and G) ChIP assays were performed with 
CT-ECFC transfected with scrambled siRNA (siCT) or SIRT1 siRNA (siSIRT1) (N = 3–5). Chromatin was 
immunoprecipitated with antibodies against SIRT1 (D), H3 and H3K9Ac (G). The precipitated genomic 
DNA was analyzed via RT-qPCR using primers for the specific promoter (Prom_2 and 8) and the enhancer 
(Enh_1 and 2) regions. (E and H) ChIP assays of PT-ECFC transfected with pCMV (Empty) or pCMV-SIRT1 
(N = 3). The chromatin was immunoprecipitated with antibodies against SIRT1 (E), H3 and H3K9Ac (H). The 
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SIRT1 enrichment at the distal 5′ regulatory region (−437 to −329 bp) and in the first strong enhancer region of 
intron 1 (+3,005 to +3,196 bp) in CT-ECFC (Fig. 7B). Prematurity led to significantly decreased SIRT1 binding 
at these regions (Fig. 7C), suggesting that SIRT1 directly binds in proximity to the MAP2K6 TSS to regulate its 
transcription.
Specifically, increased H3K9ac, a mark of active chromatin and previously identified as a specific SIRT1 target35, 
was also enriched at the TSS and at the first strong enhancer region of PT-ECFC compared to that of CT-ECFC 
(Fig. 7F), suggesting that H3K9acplays a critical role in PT-induced MAP2K6 mRNA expression.
To further investigate whether SIRT1 regulates the H3K9Ac level on MAP2K6, we knocked-down SIRT1 
using siRNA transfection in CT-ECFC or overexpressed it in PT-ECFC. SIRT1 silencing decreased SIRT1 bind-
ing to these regions and significantly increased the H3K9Ac level on the MAP2K6 enhancer (Fig. 7D and G). 
Conversely, in spite of SIRT1 binding to MAP2K6 regulatory regions, SIRT1 overexpression almost completely 
removed H3K9Ac at the first strong enhancer in PT-ECFC (Fig. 7E and H). Together, these results further indi-
cate that SIRT1 binding might suppress MAP2K6 expression by modifying H3K9 acetylation at its first strong 
enhancer.
Discussion
In the context of SIPS affecting PT-ECFC, we show that PT-ECFC develop a SASP characterized by increased 
levels of inflammatory cytokines and EMP able to propagate endothelial senescence. This study identifies a new 
epigenetic mechanism linking the SIRT1 and p38MAPK pathways to control the biogenesis of EMP by senescent 
ECFC. We showed that SIRT1 deficiency induces a signaling pathway involving the sequential accumulation of 
active MMK6 and p38MAPK, which mediate EMP release. For the first time, MKK6 expression was shown to be 
negatively regulated by SIRT1 at the chromatin level, through deacetylation of histone H3 lysine 9 in its promoter 
region (Fig. 7I).
ECFC are attracting increasing interest in vascular disease modeling to probe mechanisms of endothelial 
pathogenesis and to delineate therapeutic targets, in particular in conditions associated to adverse intrauterine or 
perinatal environments such gestational diabetes, growth restriction or prematurity10, 12, 36, 37. Indeed, antenatal 
and postnatal stressors can significantly affect PT-ECFC, which are more vulnerable at this stage of development, 
corresponding to the third trimester of gestation38, compared to CT-ECFC10, 12, 39. Altered ECFC functions, medi-
ated by disruption of proangiogenic pathway and accelerated senescence, may compromise the endothelial repair 
capacity with significant involvement in the progression of endothelial dysfunction8, 13, 14, 26 and development of 
subsequent diseases, such as bronchopulmonary dysplasia or retinopathy. Nevertheless, the spectrum of the par-
acrine effectors of senescent ECFC has never been fully investigated. Here, we demonstrated that PT-ECFC, pre-
senting a SIRT1-dependent accelerated senescence12, established a SASP, as evidenced by the enhanced secretion 
of the typical pro-inflammatory cytokines, such as IL6, that correlated with the level of cell senescence and low 
gestational age. Our results are consistent with previous reports describing IL6 as the most predictive marker in 
cord blood of preterm birth40. Furthermore, we observed that the conditioned medium from PT-ECFC induces a 
proadhesive phenotype in non-senescent naïve endothelial cells, suggesting that the SASP of PT-ECFC may affect 
vascular health by actively participating in the low-grade proinflammatory status associated with prematurity.
In addition to soluble factors, increased release of EV from senescent cells constitutes a new mechanism for 
intercellular communication16, 41. The association of increased vesiculation and endothelial senescence has been 
recently described in in vitro models of replicatively senescent endothelial cells42, 43 but remains poorly charac-
terized in ex-vivo endothelial models of SIPS. Interestingly, we showed that prematurity-associated senescence 
of ECFC leads to increased production of EMP, as identified by diameter size range and Annexin-V+ staining. In 
addition, PT-EMP levels correlate with senescence, gestational age and IL6 levels. Previous studies demonstrated 
that senescent cells promote paracrine senescence in culture models and in mouse models of oncogene-induced 
senescence in vivo20. The novelty of our study is to identify the major contribution of the vesicular fraction of 
the secretome in mediating such effect. Indeed, purified EMP from PT-ECFC were able to implement a full 
senescence response in naïve HUVEC. Our findings are consistent with recent studies demonstrating that EMP 
contribute to vascular aging propagation44, 45. Together with our previous report of elevated EMP levels in cord 
blood of PT neonates5, these observations suggest that EMP are relevant participants of the ECFC-mediated 
SAPS occurring in the context of preterm birth. The molecular mechanisms by EMP from PT-ECFC can induce 
paracrine senescence require future investigation based on EMP profiling. Among the bioactive components 
conveyed by EMPs and able to act on nearby cells, miRNA deserve increasing attention. Indeed, miRNa packaged 
in EV can be transferred to target cells, exert gene silencing effect and play a role in a broad range of pathophys-
iological processes including senescence, as recently demonstrated for EV derived from bone cells, cancer cells 
or myotubes46–48. Another hypothesis may involve pro-oxidant message carried by EMP from senescent cells43. 
Nevertheless, the strongest paracrine pro-senescent effect was obtained for unprocessed PT-media and remov-
ing the EMP from the secretome did not completely abrogate the biological activity, suggesting the presence of 
both soluble and vesicular factors acting in concert to trigger paracrine senescence mechanisms. Some reports 
indicate that EV released upon inflammatory stimulation can contain cytokines such as members of IL-1 family 
or IL-649–51. In our study, analysis of the proadhesive phenotype of HUVEC co-cultured with PT-EMP demon-
strated that PT-EMP have not a prominent role in the pro-inflammatory response orchestrated by the SASP. This 
precipitated genomic DNA was analyzed via RT-qPCR using primers for the specific promoter (Prom_2 and 
8) and enhancer (Enh_1 and 2) regions. The data for all of the bar graphs are presented as the means ± SEM. 
(Statistical analysis: Two-way ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001). (I) Proposed signaling mechanism 
controlling the release of EMP and their functional impact in the SIPS context of prematurity.
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data may indicate that despite the relationship between EMP and IL-6 levels released by PT-ECFC, pro-senescent 
EMP do not carry biologically relevant amounts of IL-6. However, elevated levels of circulating microparticles 
are associated with a number of cardiovascular and inflammatory pathologies (e.g., hypertension, diabetes and 
metabolic syndrome), and microparticles are known to actively contribute to the pathogenesis of cardiovascular 
diseases, including inflammation22, 52. Thus, a potential role of senescence-associated EMP in low-grade and pro-
longed endothelial activation cannot be ruled out. In addition to their increased production levels, the qualitative 
differences in the bioactivities of EMP generated by senescent ECFC reinforce the notion that the multifaceted 
role of EMP are strongly dependent upon the cellular context associated with their formation.
Given the detrimental role of EMP on endothelial homeostasis, knowledge of the molecular mechanisms 
governing EMP biogenesis in senescent cells is challenging. SIRT1 possesses protective roles against vascular 
aging and resultant cardiovascular diseases53. Although the beneficial effect of SIRT1 on endothelial senescence 
has been extensively studied, its direct role in the regulation of SASP is poorly described. Recently, a role of SIRT1 
deficiency in the regulation of SASP components, such as IL6, IL8 and plasminogen activator inhibitor (PAI) 
expression, has been described in fibroblastic cell lines and endothelial cells undergoing replicative senescene54, 55. 
Here, using strategies allowing the modulation of SIRT1 level in ECFC, we assigned to SIRT1 a critical role in 
the control of senescence-associated EMP biogenesis. This could be consistent with a recent observation show-
ing that increased EMP levels accompanied a decreased mitochondrial biogenesis through a SIRT1-dependent 
mechanism56. While we do not exclude the involvement of alternative mechanisms impacting on EMP biogenesis, 
our results establish a new link between the deficiency of SIRT1 and EMP release involving MKK6/p38MAPK/
Hsp27signaling pathway. The data presented here have focused on the activation of the p38MAPK pathway and the 
role of specific upstream MAPK Kinase upon SIRT1 defect. Although both MKK3 and MKK6 are required for the 
p38MAPK phosphorylation in response to environmental stresses, we observed that SIRT1 defect induces the activa-
tion of MKK3/6 through only an upregulation of MKK6, which participates to the activation of p38MAPK and sub-
sequently, to the occurrence of SIPS as well as senescence-associated EMP release. Our findings are in agreement 
with prior studies revealing p38MAPK pathway as an upstream mediator in senescence and SASP induction19, 57, 58  
as well as playing a major role in MP shedding23, 30. In endothelial cells, Hsp27 phosphorylation, mediated by 
p38MAPK signaling pathway, is thought to play an important role in actin cytoskeletal rearrangement, mem-
brane blebbing, and EMP generation31, 32. Here, we demonstrate that selective activation of p38MAPK in response 
to SIRT1 defect is required for Hsp27 phosphorylation and associated EMP formation. Together, these data sug-
gest that the environmental stress of the perinatal period might modulate senescence and the secretory profile 
through the SIRT1/MKK6/p38MAPK-dependent pathways.
Importantly, the SIRT1 modulation experiments argue in favor of a primary role for SIRT1 deficiency over 
MKK6 dysregulation. Indeed, we observed that the deletion of SIRT1 in ECFC increased MKK6 expression and 
that MKK6 expression negatively correlated with SIRT1 level. Previous studies demonstrated that SIRT1 is asso-
ciated with specific changes in chromatin during aging and represses several genes by regulating the chromatin 
structure through its histone deacetylase activity55, 59, 60. For the first time, our data identify MKK6 (MAP2K6) as a 
direct target of SIRT1, which bound to its promoter and represses it at chromatin level. Of note, we demonstrated 
that H3K9Ac enrichment, a hallmark of transcription activation, at the MKK6 enhancer plays an important role 
in senescence-induced MKK6 upregulation in PT-ECFC and is regulated by the deacetylase activity of SIRT1. 
Thus, SIRT1-mediated increase in open chromatin at the MKK6 promoter may be crucial for its activity. In line 
with this, previous reports indicated that accumulation of active chromatin markers such as H3K9Ac was associ-
ated with SIRT1 depletion and increased expression of pro-aging and inflammatory genes35, 61. Thus, repression of 
secretory profiles (consisting of soluble factors and MP) may contribute to the anti-aging effect of SIRT1, leading 
to protection against the endothelial dysfunction of age-associated vascular diseases. However, future studies are 
needed to identify the mechanism that targets SIRT1 to MAP2K6 locus in ECFC. Such mechanism is likely to play 
an important role in repressing MKK6 expression and senescence-associated phenotype.
Finally, this work and our previous data that highlight the importance of SIRT1 in endothelial homeosta-
sis may expose new reversion strategies with global effects on senescence and its consequences in the prema-
turity model. Among them, various environmental, lifestyle and pharmacologic interventions, such as caloric 
restriction, exercise, and resveratrol, are now well-appreciated for their capacity to modulate SIRT1 and related 
post-translational modifications62, 63. Correcting the function of SIRT1, a critical modulator of the signal-
ing pathways controlling aging-related processes and the balance of histone acetylation, may thus emerge as a 
promising therapeutic target53. In addition, the SASP is becoming an obvious pharmaceutical target to correct 
senescence-associated effects. Therefore implementation of “senolytic” therapy, recently reported64, has been con-
sidered to reduce the SASP contribution. Another perspective could be to limit the biogenesis of EMP as part of 
the SASP. Our study not only provides news insights into the molecular mechanisms of MP formation in the con-
text of SIPS and their potential role in preterm birth-associated vascular risk, but also opens avenues regarding 
new targeted therapeutic strategies for maintaining vascular homeostasis56, 65.
In conclusion, this study demonstrates that SIRT1 deficiency acts as a major determinant of EMP biogenesis 
associated with SIPS of endothelial cells through a novel mechanism involving the upregulation of MKK6 gene 
expression. Targeting the molecular pathways that link SIPS, gene expression changes and SASP components may 
offer new perspectives to control the progression of vascular alterations in individuals born preterm and, more 
generally, to limit endothelial pathogenesis in accelerated aging-related vascular diseases.
Methods
Detailed methods are provided in the online data supplement.
Patients. Eighteen term (control, gestational age (GA) >37 weeks, appropriate weight) and twenty-nine pre-
term neonates (GA 24 to 35 weeks with appropriate or small weight for GA), were included. Exclusion criteria 
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were congenital viral infections, major congenital heart or structural brain malformations, genetic abnormalities 
and metabolic diseases. This research was approved by a local ethic committee Assistance Publique Hôpitaux de 
Marseille and the study was performed conform the declaration of Helsinki. All the parents have provided written 
informed consent for the use of cord blood. The patient characteristics are shown in Table S1.
Isolation of endothelial colony-forming cells. ECFC were isolated and expanded from mononuclear 
cell fraction (MNC) obtained from the cord blood of term (CT) and preterm (PT) neonates, cultured and charac-
terized as previously described12. ECFC were used between the third and fourth passage.
Antibody arrays. Conditioned media for antibody array analysis were prepared by washing cells with PBS 
and incubating them in basal medium for 48 h. The conditioned media were collected in a centrifuge tube, and 
the cells remaining on the dish were counted to normalize conditioned media volumes by cell number. The con-
ditioned media were clarified by brief centrifugation, 0.2 µm filtered, diluted with a serum-free medium to a con-
centration equivalent to 1.35 × 105 cells per 1.3 ml, and applied to the antibody arrays (Raybiotech; AAH-CYT-1) 
as described previously by Freund et al.19 and as recommended by the supplier. The signals were detected using a 
G-BOX Imaging System (GeneSys) and were analyzed using specific software (GeneTools, Syngene). Signals were 
averaged and displayed as described in the figure legend.
ELISA. Conditioned media were prepared by incubating cells for 48 h as described above. The CM were ana-
lyzed using the Human IL-6 ELISA Kit II and reagents, following the procedures described by the manufacturer 
(BD OptEIATM; 550799).
Counting and measuring particles. Tunable resistive pulse sensing. The concentration and size distribu-
tion of particles was analyzed with TRPS (qNano, Izon Science Ltd, Christchurch, New Zealand), a relatively new 
technology that allows the detection of particles passing through a nanopore by way of single-electrophoresis66. 
Calibration was performed using CPC200 OR SKP400 calibration particles (Izon) as a standard according to 
the manufacturer’s instructions. Data were recorded and analyzed using the Izon Control Suite software version 
3.2.2.234.
Flow cytometric analysis of EMP. EMP were analyzed using a Gallios flow cytometer, as previously described 
by Robert et al.67. Briefly, conditioned medium was collected after 48 hours of ECFC culture (passage 3 to 4) in 
0.22 µm filtered complete medium. After two initial centrifugation to discard debris (300 × g, 5 minutes) and 
apoptotic bodies (2000 × g, 15 minutes), EMP in resulting supernatant were quantified withth Annexin A5-FITC 
(AnnV-FITC, Tau Technology BV, Netherlands). CytoCount beads (Cyto-Count, Dako, Copenhagen, Denmarrk) 
were added as internal standard to samples before FC analysis to determine the concentration of EMP. The sam-
ples analyses were performed with the Kaluza® Analysis software (Beckman Coulter), as already described68, 69.
Functional Analysis. Preparation of Conditioned Medium. Conditioned medium (CM) was collected after 
48 hours of incubation with PT or CT-ECFC in completed medium and then clarified by two serial centrifugation 
steps (300 g for 5 min and 2000 g for 15 min, at 4 °C) to remove cells debris and apoptotic bodies. CM was stored at 
−80 °C for subsequent analyses. Fresh CM was used for EMP isolation and EMP-free CM preparation.
Microparticles Isolation. To obtain EMP fractions, clarified CM was subjected to differential ultracentrifugation 
steps (70,000 g; 90 min, from 4 to 8 °C). EMP-free CM was obtained after the first ultracentrifugation, 0.2 µm 
filtered to remove vesicles > 200 nm, and stored at −80 °C for subsequent analysis. The resultant EMP pellet was 
washed twice in PBS in the same conditions. The final pellet containing the EMP fractions were diluted in EBM2 
and stored at −80 °C until subsequent use. The number of resulting EMP was quantified using high-sensitive flow 
cytometry as described above. The high-speed last wash supernatant was used as control (vehicle).
Cell culture. Human umbilical venous endothelial cells (HUVEC) were isolated from term neonates cord 
vein according to the method of Jaffe et al.70 and used at the fourth passage. HUVEC were cultured in EGM2 
media (Lonza) and cells were stimulated with CM ± depleted in EMP or in complete medium with vehicle (SN), 
CT-EMP or PT-EMP (50 EMP/Cell).
Senescence-Associated-ß-galactosidase (SA-ß-gal) staining. SA-ß-Gal activity was performed using a Promokine 
Senescence detection kit (PK-CA577-K320, PromoCell) according to the manufacturer’s instructions. Percentage 
of SA ß-gal positive cells was counted in 10 randomly selected microscopic fields (magnification ×20; 400–600 
cells).
Proliferation assay and cell cycle analysis. Proliferative capacity was analyzed using a bromodeoxyuridine (BrdU) 
incorporation assay (Roche Molecular Biochemicals) according to the manufacturer’s instructions. Cell cycle 
analysis was conducted by using a propidium iodide-based flow cytometry protocol. HUVEC were incubated for 
24 hours with CM or EMP from each condition, harvested, fixed with 70% cold ethanol, and stained with propid-
ium iodide. At least 10,000 events were acquired per sample with a Gallios flow cytometer system and analyzed 
using Kaluza® Analysis software (Beckman Coulter).
THP-1 adhesion to HUVEC. THP-1 monocytic cells were cultured in RPMI 1640 with 10% heat-inactivated 
FCS. Adhesion of the monocytic cell line THP-1 to HUVEC was performed as described by Akeson et al.71 using 
calcein-labeled cells. HUVEC were stimulated with CM or EMP from each condition, for 48 h. At the end of the 
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stimulation, calcein-labeled THP-1 were incubated with HUVECs for 30 min in RPMI medium. Adhesion to 
HUVEC was measured according to the method published by Vaporcyan et al.72. Experiments were performed 
in triplicates.
Transfection. PT-ECFC were transfected with the pCMV-Sport6 expression vector (Empty) or the 
pCMV-Sport6-SIRT1 plasmid (NIH_MGC_91 clone) using the jetPEITM-HUVEC in vitro DNA transfection 
protocol (Polyplustransfection SA, Illkirch, France). CT-ECFC were transfected with the SignalSilence® SIRT1 
siRNA (#12241, Cell Signaling) or SignalSilence® Control siRNA using the jetPRIME in vitro siRNA transfection 
protocol (Polyplustransfection SA, Illkirch, France).
Drug Treatment. ECFC were incubated with 1μM Resveratrol (RSV) (Calbiochem, La Jolla, USA), 2 µM 
SB203580 (p38MAP Kinase inhibitor) suspended in DMSO. For nicotinamide (NAM), medium containing 1 mM 
NAM was added to cells. All the doses for drug treatment were determined by dose and time-response experi-
ments in pilot experiments or previous studies12. Control cells were mock-treated with DMSO.
Western Blot. After transfections and/or treatment with chemicals or not, cells were lysed for the 
Western Blot assay. Bands were incubated with primary antibodies against SIRT1 (#2493),p16INK4a (#4824), 
p21WAF (#2947), p53 (#9282), MKK6 (#8550),MKK3 (#5674), Phospho-MKK3/MKK6 (#9236), Phospho-p38 
MAP Kinase (#9211), p38 MAP Kinase (#9212), Phospho-Hsp27 (#2401), Phospho-MAPKAPK2 (#3007), 
Phospho-ATF2 (#5112) and actin (#8457) purchased from Cell Signaling Technology (Danvers, MA) and used 
at the recommended dilution for immunoblotting (1:1000). Raw data presenting full-length blots bands with 
molecular size markers are shown in Figure S9.
RNA isolation and quantitative RT-PCR. Total RNA was extracted using the mirVana miRNA Isolation 
Kit (Ambion), according to the manufacturer’s recommendations. Two-step RT-PCR was performed. Total RNA 
was reverse transcribed into cDNA using the High Capacity cDNA Archive Kit (Applied Biosystems, Foster 
City, California, USA). cDNA product was amplified in a 20 µl reaction on MxP3000 (Stratagene, NL) using the 
Brillant QPCR Master Mix (Stratagene, La Jolla, CA) using pre-designed primers for SIRT1 (HS01009003_m1), 
p16INK4a (HS00233365_m1), p21WAF(HS00355782_m1), p53 (HS01034249_m1), MAP2K6 (HS00992389_m1) 
and RPL13A (HS00204173_m1) (Applied Biosystems). Each sample was run in duplicate, and the relative fold 
change was determined using the 2−ΔΔCT methods with CT-ECFC as baseline, normalized to RPL13A expression.
Microarrays. The microarray study was performed using microarrays chip that included 45,000 probes (1 
microarray for each sample, 4 × 44 K Whole Genome Microarray G4112F) and the One-Color Microarray-Based 
Gene Expression Analysis based on the Agilent Technologies procedures73. cRNA labeling and hybridization 
performance were performed and all parameters checked were found within the manufacturers specifications. 
Signal intensities on 20 bit tiff images were calculated by Feature Extraction software (FE, Version 8.5; Agilent 
Technologies). Data analyses were conducted with GeneSpring GX software (Vers.13.1.1; Agilent Technologies). 
We considered genes to be differentially expressed when the adjusted p value was below 0.05, as determined 
by a moderated T-test supplemented with Benjamini-Hochberg multiple testing corrections, and the abso-
lute fold-change (FC) was higher than 1.5. Unsupervised analyses were performed using principal component 
analysis (PCA) and hierarchical clustering. The average linkage was based on the Pearson correlation distance. 
Microarray data are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under accession num-
ber E-MTAB-4860.
Chromatin Immunoprecipitation (ChIP) and real-time PCR. Chromatin immunoprecipitation was 
performed as described previously74. Precleared chromatin was incubated overnight at 4°C with 5 μl of pri-
mary antibodies specific for SIRT1 (#07-131) acH3K9 (#07-352) and H3 (#04-928) purchased from Millipore. 
After collection of immune complexes, DNA was recovered and quantified. Analysis of ChIP DNA samples was 
performed by quantitative PCR with the specific promoter regions described in the Supplemental Table VII. 
Real-time PCR experiments were performed using the SYBR® Premix Ex TaqTM (Takara Bio Inc, Japan) and 
analyzed using the stepOnePlus™ Real-Time PCR System (Applied Biosystems). qPCR values were normal-
ized to the values obtained with the positive control (Chromosome 5) and to input DNA. For histone mark 
ChIP, after Chromosome 5 normalization, data were further normalized for the total histone H3 signal using the 
(2Ct(IP)-Ct(Ref)) equation.
Statistical Analysis. All the statistical analyses were performed using the software GraphPad Prism software 
and significance was calculated with 95% confidence interval (alpha < 0.05) Data are expressed as means ± SEM. 
Demographic data of the preterm and term populations were analyzed qualitatively using the chi2 test of Pearson 
and quantitatively using the 2-tailed unpaired t test. Normality was confirmed with a D’Agostino and Pearson 
omnibus test. For data normally distibuted, statistical significance was assessed by an unpaired or pair Student 
t-test, as appropriate. For data not normally distributed, we used a Mann-Whitney or Wilcoxon test, as appropri-
ate. When ANOVA was utilized, post-hoc intergroup comparison were analyzed for statistical significant differ-
ences using either Tukey’s (all group compared to each other) or Dunnet’s (groups compared to control group) 
methodology, as appropriate. Statistical significance was accepted at p-value < 0.05.
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